Access to current antimicrobial agent surveillance data is an important prerequisite for the optimal management of patients with hospital-acquired infections. The present study used data collected in 2000 to 2001 from 670 laboratories in Europe (France, Germany, Italy, and Spain), Canada, and the United States to report on the in vitro activities of ceftriaxone, cefotaxime, and comparative agents against >125,000 isolates of gram-negative bacteria from hospitalized patients. All but two isolates of Enterobacteriaceae (one isolate of Proteus mirabilis from France and one isolate of Morganella morganii from Canada) were susceptible to imipenem. The susceptibility of Escherichia coli to ceftriaxone or cefotaxime was >97% in each country, and for P. mirabilis, susceptibility was 99% in each country except Italy. In contrast, susceptibility of E. coli to ciprofloxacin varied from 80.5% (Spain) to 94.0% (France); levofloxacin susceptibility ranged from 75.2% (Spain) to 91.6% (United States). Among Klebsiella pneumoniae and Klebsiella oxytoca isolates, ceftriaxone and cefotaxime susceptibilities ranged from 86.6 to 98.7% and 83.5 to 99.7%, respectively, depending upon the country. Considerable geographic variation in the susceptibilities (generally 85 to 95% susceptible) of Serratia marcescens and M. morganii to ceftriaxone and cefotaxime were observed. For S. marcescens, susceptibility to piperacillin-tazobactam varied from 81.5% (France) to 94.1% (Italy) and susceptibility to ciprofloxacin ranged from 66.2% (Germany) to 90.7% (Spain). Enterobacter cloacae and Enterobacter aerogenes were less susceptible to ceftriaxone and cefotaxime than were the other species of Enterobacteriaceae studied. The present study demonstrated that established parenteral expanded-spectrum cephalosporin antimicrobial agents retain significant in vitro activity against many clinically important gram-negative pathogens.
Gram-negative bacteria remain important hospital pathogens, particularly for critically ill patients, and appropriate antimicrobial treatment is often critical to decreasing morbidity and mortality among hospitalized patients with infections (3, 8) . Given the propensity for resistance to develop to all available antimicrobial agents, the publication of current antimicrobial susceptibility data are important, particularly for agents or classes of agents that have been frequently used clinically for prolonged periods of time and upon which physicians constantly depend. Expanded-spectrum cephalosporins such as ceftriaxone and cefotaxime are broad-spectrum agents that have been widely prescribed by physicians in Europe, Canada, and the United States for hospitalized patients with a variety of infections for almost 20 years. The intent of the present study was to provide an update on the in vitro activity of expanded-spectrum cephalosporins and comparator antimicrobial agents against gram-negative bacteria from hospitalized patients in France, Germany, Italy, Spain, Canada, and the United States by using The Surveillance Network (TSN) databases (Focus Technologies, Herndon, Va.). The implications of recent surveillance data for the therapy of hospitalacquired infections are discussed.
MATERIALS AND METHODS
In 2000 to 2001, TSN databases assimilated antimicrobial susceptibility testing and patient demographic data from networks of hospitals in several countries, including France (n ϭ 63), Germany (n ϭ 168), Italy (n ϭ 48), Spain (n ϭ 21), Canada (n ϭ 87), and the United States (n ϭ 283), and these were used as the data source for this study (17) . Laboratories contributing to TSN databases are all nationally accredited and are invited to participate in TSN based on factors such as hospital type (university teaching hospital or community hospital) and antimicrobial susceptibility testing method used as well as the bed size, patient population, and geographic location of the hospital(s) they serve (17) . All isolates reported in TSN were identified at the participating institutions by routine methods in use at each laboratory. Antimicrobial susceptibility testing of patient isolates is conducted onsite by each participating laboratory as a part of its routine diagnostic testing. Only data generated by using nationally approved (Food and Drug Administration-approved in the United States) testing methods with MIC results interpreted according to NCCLS (Germany, Italy, Spain, Canada, and United States) (13) and SFM (Société Francaise de Microbiologie; France) recommendations (18) were included in the datasets analyzed in this study. Antimicrobial agent susceptibility data from Germany and Spain that were interpreted by breakpoints other than those of the NCCLS were excluded from the datasets analyzed; all data in TSN from Italy, Canada, and the United States were interpreted by using NCCLS breakpoints. In addition, a series of qualitycontrol filters (proprietary critical rule sets) were used to screen susceptibility test results for patterns indicative of testing error; suspect results are removed from analysis for laboratory confirmation (17) . In TSN, any result from the same patient with the same organism identification and the same susceptibility pattern received within 5 days is considered a repeat culture and is counted only once in the database.
In the present study, TSN results from 1 January 2000 to 31 December 2001 were used to determine the rates of antimicrobial susceptibility for 15 antimicrobial agents among prevalent gram-negative species isolated from hospitalized patients in Europe, Canada, and the United States. Data from patients identified as nursing home residents and hospital outpatients in hospital laboratory information systems were excluded from the analysis. An inpatient isolate was defined as such by each hospital participating in TSN. The TSN database presumes the evidence of infection, but no clinical correlates are applied universally. Thus, the data for gram-negative bloodstream and urine cultures are much more likely to reflect infection causally than the data for isolates from wounds and sputum cultures. Nevertheless, the data from microbiology laboratories are often used to guide therapy in hospital-associated pneumonia and often in skin and soft tissue infections. Overall data from all specimen sources were analyzed, as were susceptibility rates among organisms commonly isolated from patients with specific infection types. Isolate results were reported only for bacterial species-antimicrobial agent combinations in which 50 or more results were available for a specific specimen source in a country. In TSN, all isolates are not tested against all agents and variation can be observed for antimicrobial agents of the same class such as expanded-spectrum cephalosporins (ceftriaxone and cefotaxime) and fluoroquinolones (ciprofloxacin and levofloxacin) for which similar in vitro activities have been previously demonstrated.
RESULTS
The cumulative 2000 to 2001 antimicrobial susceptibilities of eight species of Enterobacteriaceae and Haemophilus influenzae from hospitalized patients are shown (Table 1) . Data from both intensive-care unit (ICU) and non-ICU hospital inpatients are combined. All members of the family Enterobacteriaceae were susceptible to imipenem except for one isolate of Proteus mirabilis from France and one isolate of Morganella morganii from Canada. Susceptibility to amikacin exceeded 98% for the majority of species of Enterobacteriaceae in each country studied, and generally, susceptibility to gentamicin was Ͼ90%. Escherichia coli susceptibility to ceftriaxone or cefotaxime was 97% or greater in each country studied. In contrast, susceptibility to amoxicillin-clavulanate varied from 69.9% (France) to 85.8% (Spain), susceptibility to ciprofloxacin varied from 80.5% (Spain) to 94.0% (France), and susceptibility to levofloxacin varied from 75.2% (Spain) to 91.6% (United States).
Ninety-nine percent of P. mirabilis isolates from each country except Italy (81.0% and 71.9%, respectively) were susceptible to ceftriaxone or cefotaxime. For Klebsiella pneumoniae and Klebsiella oxytoca, ceftriaxone or cefotaxime susceptibilities ranged from 86.6 to 98.7% and 83.5 to 99.7%, respectively, depending upon the country. Considerable variation in the susceptibilities to ceftriaxone and cefotaxime of Serratia marcescens and M. morganii were also noted for isolates tested within the same country and among countries, but generally, 85 to 95% of isolates of both species were susceptible to ceftriaxone or cefotaxime. For S. marcescens, susceptibility to piperacillin-tazobactam varied from 81.5% (France) to 94.1% (Italy), and susceptibility to ciprofloxacin varied from 66.2% (Germany) to 90.7% (Spain).
Enterobacter cloacae and Enterobacter aerogenes were less susceptible to ceftriaxone and cefotaxime than were the other species of Enterobacteriaceae studied. Susceptibilities to cefepime, ceftriaxone, and cefotaxime were similar for E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis. Cefepime susceptibilities were greater than those to ceftriaxone and cefotaxime for Enterobacter spp., S. marcescens, and M. morganii. All isolates of H. influenzae were susceptible to ceftriaxone, cefotaxime, and cefepime. Ceftazidime nonsusceptibility ranged from 0.9% (France) to 3.5% (Italy) for E. coli and from 1.6% (Canada) to 16 . In a few instances it seems interesting that the antimicrobial agent-pathogen pairs showed reduced susceptibilities across several antimicrobial agents. For example, in Italy the range of susceptibilities for P. mirabilis for all six antimicrobial agents varied from 52.6 to 78.4%, the lowest range for all the countries studied. However, for S. marcescens, the lowest range was seen in France, with susceptibilities from 69.9 to 90.9% across five antimicrobial agents tested. Table 4 depicts the cumulative 2000 to 2001 data for the susceptibilities of five species of Enterobacteriaceae, H. influenzae, and P. aeruginosa isolated from lower respiratory tract infection specimens to antimicrobials. Generally, lower respiratory tract isolates of E. coli were 1 to 5% less susceptible than were all isolates combined to expanded-spectrum cephalosporins, ciprofloxacin, gentamicin, and TMP-SMX ( a To estimate antimicrobial susceptibilities among patients with complicated urinary tract infections, isolate specimen sources were limited to invasive specimen sources (catheterized urines, suprapubic bladder aspirates, nephrostomy, cystoscopic urine aspirates, and ureter; clean-catch urine and catheter tip isolates were excluded) from ICU and non-ICU inpatients, both males and females Ն18 years of age. The "Other Enterobacteriaceae" category was created for complicated urinary tract infection isolates to include Citrobacter spp., Enterobacter spp., Providencia spp., and Serratia spp. from the respiratory tract were less susceptible than P. aeruginosa isolates from the bloodstream in each country studied (Table 3) to amikacin (0.4 to 12.9% less), ceftazidime (3.3 to 9.3% less), ciprofloxacin (8.3 to 15.1% less), gentamicin (6.2 to 11.6% less), imipenem (6.8 to 13.4% less), and piperacillintazobactam (0.1 to 6.8% less). Cefepime susceptibilities were also lower (8.4 to 12.3%) for P. aeruginosa isolates from the respiratory tract than those from the bloodstream for each country (with data) except Italy, where susceptibilities were slightly lower (1.1%) among bloodstream isolates. Antimicrobial susceptibilities of gram-negative bacteria isolated from skin and soft tissue specimens are summarized in Table 5 and were similar to the results reported for all isolates (Table 1) . In general, isolates of P. aeruginosa isolated from skin and soft tissue specimens were more susceptible to amikacin, cefepime, and imipenem than isolates from the bloodstream (Table 3) . (Canada) of isolates were susceptible to cefotaxime. Differences in susceptibilities relative to all isolates were greatest for expanded-spectrum cephalosporins (up to 10% lower susceptibility among isolates from ICUs) and gentamicin (9.5%) for K. pneumoniae. Differences in susceptibility for isolates of E. coli from ICU patients relative to all isolates combined were variable and did not demonstrate an observable trend.
DISCUSSION
The goal of antimicrobial chemotherapy is to facilitate the eradication of infecting organisms from patients in a timely and safe manner while minimizing the emergence and spread of resistance. Best outcomes occur clinically if patients are given empirical therapy to which the organism is susceptible on the day infection is suspected clinically (8, 11) . Our data indicate that susceptibility to ceftriaxone, piperacillin-tazobactam, imipenem, and aminoglycosides have remained relatively stable among most species of Enterobacteriaceae from 1996 to 2001 in the United States (10) ( Table 1 ). The potency of ceftriaxone and cefotaxime against E. coli and Klebsiella suggests that single-agent therapy directed against those bacteria may be successful even in severely compromised hosts (25) . However, the recent emergence of extended-spectrum ␤-lactamases and stably derepressed mutants that hyperproduce chromosomal ␤-lactamases has the potential to diminish the activity of all expanded-spectrum cephalosporins against these pathogens. In the United States, the prevalence of potential extended-spectrum ␤-lactamase-producing isolates of E. coli and K. oxytoca (MICs of ceftazidime interpreted as intermediate and resistant) increased from 0.9 to 1.6% and from 2.9 to 5.9%, respectively, between 1996 and 2000 (10) . The present report and previous reports indicate that fluoroquinolone susceptibility appears less stable than susceptibility to other classes of antimicrobials and has decreased over time in a consistent stepwise manner for members of the family Enterobacteriaceae, P. aeruginosa, and S. aureus in both the United States and Europe (4, 6, 10, 12) . The widespread cumulative use of fluoroquinolones (ciprofloxacin and levofloxacin) may be accelerating the development of resistance to these agents and may be the driving force behind increases in resistance (2, 12, 14, 15) . Fluoroquinolone resistance among species of gram-negative bacilli appears to be found more commonly as a component of multidrug-resistant phenotypes than as a single-agent resistance phenotype (16, 24) . The potential for commonly encountered gram-negative bacilli to acquire crossresistance to several antimicrobial agents has been well documented (9, 24) .
Infections of the urinary tract are the most common nosocomial infections. They account for approximately 40% of infections and are usually catheter-associated (21) . Most bacteriuric episodes in patients with short-term catheterization result from a single species, primarily E. coli. However, K. pneumoniae, P. mirabilis, Staphylococcus epidermidis, enterococci, P. aeruginosa, and Candida are also common. Some clinical data have suggested that antimicrobial treatment of catheterized patients with symptomatic bacteriuria may not be particularly useful in preventing complications (21) . While consensus guidelines exist for the management of acute uncomplicated cystitis and pyelonephritis in otherwise healthy adult females (20) , consensus guidelines are not currently published to guide the treatment of complicated urinary tract infections. In the present investigation, an average of 97% of E. coli in the countries studied remained susceptible to ceftriaxone and cefotaxime, suggesting that these antimicrobial agents remain an important therapeutic option for complicated urinary tract infections. K. pneumoniae, K. oxytoca, and P. mirabilis were also generally Ͼ90% susceptible to ceftriaxone or cefotaxime in the countries studied. Cefotaxime and ceftriaxone susceptibility was lower for these three pathogens in Italy than the other countries studied. A recent analysis using the concept of attributable mortality (23) suggested that nosocomial bloodstream infections represent a leading cause of death in the United States (22) . In the prospective surveillance system called SCOPE, nosocomial bloodstream infections caused by E. coli, Klebsiella spp., Enterobacter spp., Pseudomonas spp., and Serratia spp. had crude mortalities of, respectively, 24, 27, 28, 33, and 26% (5). Early initiation of appropriate antimicrobial agent treatment is critical in decreasing morbidity and mortality among patients with bloodstream infections due to gram-negative organisms (3, 8) . The appropriateness of antimicrobial agent therapy should be reviewed within 24 h of the final susceptibility report becoming available from the laboratory (7). Combinations of antimicrobial agents are recommended for empirical therapy of patients with bloodstream infections, particularly for those patients with the most adverse prognostic factors (25) . Clinicians need to take into account the different rates of resistance in ICUs and wards as well as the probability of P. aeruginosa when considering empirical therapy for infections with possible Gram-negative bacillary etiologies. Ceftriaxone, cefotaxime, and cefepime all have similar indications for pneumonia, skin and skin structure infections, and urinary tract infections; only ceftriaxone and cefotaxime have an indication for the sepsis syndrome. Our data suggest that the susceptibility of E. coli (Ͼ98%), K. pneumoniae (Ͼ91%), and P. mirabilis (Ͼ99%, except Italy) to ceftriaxone and cefotaxime remains high. However, ceftazidime, cefepime, imipenem, and meropenem appear most active against P. aeruginosa (25) ( Table 3) .
Pneumonia accounts for 15 to 20% of all hospital-acquired infections (19) ; in ICUs, pneumonia is generally the most common infection type. Hospital-acquired pneumonia accounts for the majority of deaths attributed to nosocomial infections (19) , and Enterobacteriaceae, P. aeruginosa, Streptococcus pneumoniae, H. influenzae, and Staphylococcus aureus are the primary etiologic agents. Ceftriaxone and other nonpseudomonal expanded-spectrum cephalosporins are recommended by the American Thoracic Society for the treatment of patients with mild to moderate hospital-acquired pneumonia, provided that patients do not have risk factors which might alter the likely causative pathogens (1). Nonpseudomonal expanded-spectrum cephalosporins are also recommended for those patients with severe disease, provided that infection occurs within less than 5 days of hospital admission (1) . In the present study, susceptibility data for respiratory isolates (Table 4 ) and isolates from patients in ICUs (Table 6 ) support such therapies for gramnegative bacilli under current empirical guidelines.
Skin and soft tissue infections in hospitalized patients are most commonly attributable to gram-positive bacteria (S. aureus, Streptococcus pyogenes, Streptococcus agalactiae). However, gram-negative bacteria, including species of Enterobacteriaceae, may also be etiologic agents. In addition to demonstrating almost uniform susceptibility to methicillin-susceptible S. aureus, S. pyogenes, and S. agalactiae (10), susceptibility to expanded-spectrum cephalosporins such as ceftriaxone and cefotaxime is high among Enterobacteriaceae species isolated from skin and soft tissue specimen sources (Table 5 ).
In conclusion, in an international study of over 125,000 isolates from 670 laboratories, our data suggest that the susceptibilities of Enterobacteriaceae and P. aeruginosa to some classes of antimicrobial agents are decreasing, most notably to the fluoroquinolones (ciprofloxacin and levofloxacin). Certain well-established antimicrobial agents, including parenteral expanded-spectrum cephalosporins, continue to retain high rates of susceptibility against many clinically important gram-negative pathogens. With respect to aminoglycosides, the susceptibility of Enterobacteriaceae to amikacin exceeded 98% and that 
